Utilizing MRI for Earlier Diagnosis of Rheumatoid Arthritis

• Sponsor: Mayo Clinic (Other)
• Overall Status: Recruiting
• CT.gov ID: NCT03841279
• Collaborator: (none)
• Enrollment: 100
• Location: 1
• Anticipated Duration (Months): 47
• Patients Per Site Per Month: 2.1

Study Details

Study Description

Brief Summary

MRI has been shown to be helpful in identifying patients who present with undifferentiated inflammatory arthritis who will develop RA within a one year follow up period. The absence of other clinically apparent symptoms often causes delays in diagnosis of RA. The use of the MRI in conjunction with the physical examination has the potential to reduce diagnostic delay. Earlier diagnosis would allow for earlier treatment implementation for better patient outcomes.

Condition or Disease	Intervention/Treatment	Phase
Rheumatoid Arthritis	Diagnostic Test: MRI

Study Design

• Study Type: Observational
• Anticipated Enrollment: 100 participants
• Observational Model: Cohort
• Time Perspective: Prospective
• Official Title: Utilizing MRI for Earlier Diagnosis of Rheumatoid Arthritis
• Actual Study Start Date: Jan 1, 2019
• Anticipated Primary Completion Date: Dec 1, 2022
• Anticipated Study Completion Date: Dec 1, 2022

Outcome Measures

Primary Outcome Measures

1. Earlier Diagnosis of RA if MRI is utilized [1 year]

   To determine if MRI is predictive of later development of RA in patients with undifferentiated inflammatory arthritis; patients with inflammatory arthritis who receive an MRI will have earlier initiation of treatment

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

≥ 18 years old

Undifferentiated inflammatory arthritis suspected to be early RA (≥1 joint with synovitis and ≥1 other tender joint)

Symptom duration ≤1 year

Exclusion Criteria:

Unwillingness or inability to return to Mayo Clinic Rochester for research follow-up visits

Current or previous use of DMARDS

Taking ≥10 mg of prednisone a day

Contraindications to contract enhanced MRI

History of another definite autoimmune or inflammatory rheumatic disease

History of psoriasis

History of inflammatory bowel disease

Unsuitably as deemed by the principal investigator

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Mayo Clinic	Rochester	Minnesota	United States	55905

Sponsors and Collaborators

• Mayo Clinic

Investigators

• Principal Investigator: Kerry Wright, MBBS, Mayo Clinic

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

• Mayo Clinic Clinical Trials

Publications

None provided.

• Responsible Party: Kerry Wright, Principal Investigator, Mayo Clinic
• ClinicalTrials.gov Identifier: NCT03841279
• Other Study ID Numbers: 18-005455
• First Posted: Feb 15, 2019
• Last Update Posted: Apr 4, 2022
• Last Verified: Mar 1, 2022

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: Yes
• Additional relevant MeSH terms: Arthritis; Arthritis, Rheumatoid

Study Results

No Results Posted as of Apr 4, 2022